Actively Recruiting
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Led by Glaukos Corporation · Updated on 2026-03-02
610
Participants Needed
3
Research Sites
350 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
CONDITIONS
Official Title
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
- Age 18 years or older
You will not qualify if you...
- Prior incisional glaucoma surgery in the study eye
- Prior argon laser trabeculoplasty (ALT) in the study eye
- Prior minimally invasive glaucoma (MIGS) surgery in the study eye
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Glaukos Investigative Site
Grand Junction, Colorado, United States, 81501
Actively Recruiting
2
Glaukos Investigative Site
Oklahoma City, Oklahoma, United States, 73112
Actively Recruiting
3
Glaukos Clinical Site
El Paso, Texas, United States, 79922
Actively Recruiting
Research Team
S
Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
9
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here